|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Analysis of high-risk prostate cancer (PC) families with at least one confirmed case of primary brain cancer (BC) has identified a region of genetic linkage on chromosome 1p36 termed CAPB.
|
11536309 |
2001 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic studies associated the CAPB locus with familial risk of brain and prostate cancers.
|
16507112 |
2006 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Early linkage results have provided targeted candidate regions for prostate cancer susceptibility loci, including HPC1 on chromosome 1q23-25, PCAP on chromosome 1q42-43, CAPB on chromosome 1p36, linkage to chromosome 8p22-23, HPC2 on chromosome 17p, HPC20 on chromosome 20q13, and HPCX on chromosome Xq27-28.
|
14749351 |
2004 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
We evaluated the contribution of EphB2 to inherited PC susceptibility in African Americans (AA) by screening the gene for germline polymorphisms.
|
16155194 |
2006 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In total, 126 individuals (including 89 men with prostate cancer) were genotyped using markers that map to five prostate cancer susceptibility loci, namely HPC1 at 1q24-25, PCAP at 1q42.2-43, CAPB at 1p36, HPC20 on chromosome 20, and HPCX at Xq27-28.
|
14735201 |
2004 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here we have analyzed the EPHB2 gene for germline alterations in 101 individuals either with 1) CRC and a personal or family history of prostate cancer (PC), or 2) intestinal hyperplastic polyposis (HPP), a condition associated with malignant degeneration such as serrated adenoma and CRC.
|
16740153 |
2006 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that oncogenic ETS rearrangements cause a cell migration gene expression program to switch from RAS/ERK control to PI3K/AKT control and provide a possible explanation for the high frequency of PTEN, but not RAS/RAF mutations in prostate cancer.
|
24642271 |
2014 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Prostate cancer susceptibility loci that have been reported so far include HPC1 (1q24-q25), PCAP (1q42-q43), HPCX (Xq27-q28), CAPB (1p36), HPC20 (20q13), HPC2/ELAC2 (17p11) and 16q23.
|
11673416 |
2001 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
UNIPROT |
Taken together with studies indicating that EphB2 may have an essential role in cell migration and maintenance of normal tissue architecture, our findings suggest that mutational inactivation of EPHB2 may be important in the progression and metastasis of prostate cancer.
|
15300251 |
2004 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
According to our previous study, the RTK/ERK pathway containing nearly 40 genes was associated with PCa risk.
|
24177231 |
2014 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Together, we have identified an association of genetic variants and genes in the RTK/ERK pathway with prostate cancer aggressiveness, and highlighted the potential importance of CCND2 in prostate cancer susceptibility and tumor progression to metastasis.
|
28674394 |
2017 |
|
Malignant neoplasm of prostate
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Such a "mutatomics" screening of prostate cancer cell lines led to the identification of inactivating mutations in the EPHB2 gene.
|
16037637 |
2005 |
|
Prostate cancer, familial
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
We have previously shown an association between an EphB2 germline nonsense variant and risk of familial prostate cancer among African American Men (AAM).
|
21603658 |
2011 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
BEFREE |
Inactivation of EPHB2 has recently been shown to accelerate tumorigenesis in the colon and rectum, and we have previously demonstrated frequent frameshift mutations (41%) in an A9 coding microsatellite repeat in exon 17 of EPHB2 in colorectal tumors with microsatellite instability (MSI).
|
16819508 |
2007 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
BEFREE |
Taking advantage of this polymorphism within EPHB2, we surveyed the loss of heterozygosity (LOH) status of this gene in Japanese colorectal tumors.
|
11166921 |
2001 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
LHGDN |
We detected novel germline EPHB2 alterations in patients with colorectal tumors.
|
16740153 |
2006 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
BEFREE |
We detected novel germline EPHB2 alterations in patients with colorectal tumors.
|
16740153 |
2006 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
LHGDN |
Germline EPHB2 receptor variants in familial colorectal cancer.
|
18682749 |
2008 |
|
Colorectal Neoplasms
|
0.190 |
GeneticVariation
|
group |
CLINVAR |
Germline EPHB2 receptor variants in familial colorectal cancer.
|
18682749 |
2008 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In three human prostate cancer cell lines, methylation-specific-PCR was used to determine the effect of soy isoflavones (genistein and daidzein), compared to known demethylating agent 5-azacytidine as control in the promoter regions of glutathione S-transferase P1 (GSTP1), Ras association domain family 1 (RASSF1A), ephrin B2 (EPHB2) and breast cancer 1 (BRCA1) genes.
|
20668305 |
2010 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Several of these hypermethylated CpG islands are associated with genes involved in the MEK-ERK pathway, one of the most frequently disrupted pathways in cancer.
|
23143272 |
2013 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Experimental results on male BALB/c nude mice confirmed that orally administration of COP at high-dose (150 mg/kg) could suppress tumor growth, and may reduce cancer metastasis risk by inhibiting the RAS-ERK pathway in vivo.
|
28165459 |
2017 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Taken together, these studies describe the interaction of SCH772984 with ERK and identify a novel mechanism of ERK inhibitor resistance through mutation of a single residue within the DFG motif.Mol Cancer Ther; 15(4); 548-59.©2016 AACR.
|
26832798 |
2016 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this review, we will discuss diverse approaches to overcome the problem of resistance to existing anti-EGFR therapies and potential future directions for cancer therapies related to the mutational status of genes associated with EGFR-Ras-ERK and PI3K signalings.
|
25110417 |
2014 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The Ras-Raf-mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase/mitogen-activated protein kinase (Ras-Raf-MEK-ERK/MAPK) signaling pathway is at the heart of the signaling networks that control many fundamental cellular processes and Raf kinases takes centre stage in the MAPK pathway, which is now appreciated to be one of the most common sources of the oncogenic mutations in cancer.
|
25333451 |
2015 |